Strong Top-Line Growth (Q4)
Gross premiums written increased 57% year-over-year to $618.5 million in Q4 2025 (from $394.6 million), driven by voluntary sales and the assumption of ~152,000 Citizens policies.
Large Increase in Policies in Force
Policies in force reached ~493,500 at quarter end, up 44% year-over-year and up 40% from September 30, 2025.
Record Net Income and EPS
Net income more than doubled to $170.4 million in Q4 2025 (from $75.1 million prior year), with diluted EPS of $1.23; this represents roughly a 127% increase in net income year-over-year.
Exceptional Return on Equity
Quarterly ROE was 16.4% (Q4) and full-year 2025 ROE was 57.4%, despite a substantial IPO capital raise during the year.
Improved Profitability Metrics
Quarterly combined ratio improved to 38% from 60.9% a year ago; loss ratio improved to 8.3% from 26.3%, reflecting favorable prior-year development and lower catastrophe activity.
Strong Balance Sheet and Liquidity
Book value exceeded $1.1 billion, total assets of $2.9 billion, cash and cash equivalents of ~$1.2 billion, restricted cash $481.8 million, invested assets $593.7 million, and low long-term debt of $33.7 million (debt-to-capital of 2.9%).
Capital Deployment and Share Repurchases
Repurchased ~$20 million of stock in Q4 (approx. 1.2 million shares at $16.38 avg); $80 million remains available under a $120 million repurchase program.
Ambitious 2026 Financial Guidance
Company provided 2026 guidance expecting gross written premiums of $1.85B–$1.95B and after-tax net income of $455M–$470M, implying continued strong growth.
Expansion and Product Launches
Planned geographic expansion and new products: pending tailored-peril policies in NY & NJ (H1 2026), Rhode Island (H2 2026), and an excess & surplus product launch in California in the next 30–60 days.
Operational Track Record Since Launch
Since 2022, Slide reported a 55% CAGR in gross premiums written and a 7,399% CAGR in net income, underscoring rapid scaling and operating leverage.
Reinsurance Optimization
Placed a ~$320 million ILS cat bond with risk-adjusted cost down >20% year-over-year, and guidance embeds an expected reduction in reinsurance expense.